Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
neoTropIm neoadjuvant sacituzumab tirumotecan + tislelizumab in resectable squamous NSCLC
ChiCTR2600134020Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and tislelizumab in Pulmonary squamous cell carcinoma, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Pathological complete response rate and Adverse events and serious adverse events. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecantislelizumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2600134020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134020.